Review article: GLP-1 receptor agonists and glucagon/GIP/GLP-1 receptor dual or triple agonists-mechanism of action and emerging therapeutic landscape in MASLD
According to the STEP 1 trial published in the New England Journal of Medicine, patients taking semaglutide 2.4 mg (Wegovy) achieved approximately: 3% to 5% body weight loss by week 12 10% to 12% body weight loss by week 28 15% to 17% body weight loss by week 68 (maximum effect) These figures represent average outcomes in clinical trials
They may suggest switching to an injectable version or taking other steps to help you remember your dose
This is a useful data point
Traditional hangover recovery supplements often fall short for one crucial reason: poor bioavailability
Arrabal-Polo MA, Arias-Santiago S, de Haro-Munoz T, Lopez-Ruiz A, Orgaz-Molina J, Gonzalez-Torres S,